期刊
MOLECULAR THERAPY
卷 23, 期 1, 页码 171-178出版社
CELL PRESS
DOI: 10.1038/mt.2014.156
关键词
-
资金
- NIH [P50 CA126752, 1R01CA173750-01]
- Leukemia and Lymphoma Society SCOR in Lymphoma
- Alex Lemonade Stand Foundation
- St. Baldrick's Foundation
- Adrienne Helis Malvin Medical Research Foundation
- Baylor College of Medicine
- Adoptive T-cell Therapy for Lung Cancer Program
- NATIONAL CANCER INSTITUTE [R01CA173750, P50CA126752] Funding Source: NIH RePORTER
Adoptive immunotherapy with antigen-specific T cells has shown promise for the treatment of malignancies. However, infused T cells are unable to redirect resident T cells, limiting potential benefit. While the infusion of bispecific T-cell engagers can redirect resident T cells to tumors, these molecules have a short half-life, and do not self amplify. To overcome these limitations, we generated T cells expressing a secretable T-cell engager specific for CD3 and EphA2, an antigen expressed on a broad range of human tumors (EphA2-ENG T cells). EphA2-ENG T cells were activated and recognized tumor cells in an antigen-dependent manner, redirected bystander T cells to tumor cells, and had potent antitumor activity in glioma and lung cancer severe combined immunodeficiency (SCID) xenograft models associated with a significant survival benefit. This new class of tumor-specific T cells, with the unique ability to redirect bystander T cells, may be a promising alternative to current immunotherapies for cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据